# Pigmentary degenerative maculopathy in a **CYP2U1/SPG56** family

Carlo Casali, MD, PhD<sup>1,</sup> Luca Leonardi, MD<sup>1</sup>, Christian Marcotulli, MD<sup>1</sup>, Antonino Longobardi<sup>1</sup>, Alessandra Tessa, PhD<sup>2</sup>, Eugenia Storti, PhD<sup>2</sup>, Mariano Serrao, MD, PhD<sup>1</sup>, Vincenzo Parisi MD<sup>4</sup>, Filippo M Santorelli, MD<sup>2</sup>, Francesco Pierelli, MD<sup>1,3</sup>

<sup>1</sup>Dept. Scienze e Biotecnologie Medico-Chirurgiche, Rome Sapienza University Polo Pontino. <sup>2</sup> Molecular Medicine, Department of Developmental Neuroscience, IRCCS Stella Maris, Pisa, Italy. <sup>3</sup>IRCCS Neuromed Institute, Pozzilli, IS, Italy.

<sup>4</sup> IRCCS G.B. Bietti Foundation - IRCCS G.B. Bietti Foundation - Roma

**Introduction:** SPG56 is an autosomal recessive form of Hereditary Spastic Paraplegia (HSP) caused by mutations in CYP2U1, a gene involved in lipid metabolism and mitochondrial function. Herein, we report three SPG56 patients with pigmentary degenerative maculopathy as a prominent clinical feature.

## Pat 1 – Brain MRI

- Brainstem and cerebellar atrophy
- Thinned corpus callosum
- White matter changes



*Materials/Methods:* Patient 1 is a 50 year-old man, with progressive walking unsteadiness and progressive visual loss after age 30 years. His healthy consanguineous parents originated from a small village in Campania. He showed paraparetic gait, lower limbs spasticity and brisk tendon reflexes, bilateral Babisnki sign (SPRS 8/52) and mild cerebellar signs. EMG/NCS disclosed a subclinical axonal motor and sensory polyneuropathy. MRI showed mild brainstem and cerebellar atrophy as well as a moderately thinned corpus callosum. His 46-year-old sister was similarly affected with onset after age 30 years. Patient 3 is their 42 year-old first cousin on both mother's and father's side.

After extensive genetic analyses (ARSACS, SPG7, SPG11, SPG15), a homozygous c.1168C>T (p.R390\*) pathogenic mutation in the coding region of CYP2U1 was detected in all three patients, allowing a diagnosis of SGP56. As visual acuity of all patients was severely reduced (1/10 and 2/10, in patients 1 and 3 respectively), complete ophthalmologic evaluation, including (ocular fundus, OCT scan, PEV and PERG, was undertaken, which disclosed a pigmentary degenerative maculopathy



Vis	us lontano		Visus vic	Visus vicino OD:-1,50 sf=-0,50 Cyl:(45):V carattere OS:-1,75 sf= Cyl:():V carattere (T)		
OD:	-2,50 sf=-0,50 Cy	:(45):1,0/10	<b>OD:</b> -1,50 s			
os:	-2,75 sf= Cyl:():1	,0/10 (T)	<b>OS:</b> -1,75 s			
Esa	me senso Cron	natico: Ishihar	a			
OD:	22/22		<b>OS:</b> 22/2	<b>OS:</b> 22/22		
Esa	me del Fondo (	Oculare				
OD:	<ul> <li>Maculopatia atrofica. Papilla ottica rosea e a margini netti.</li> </ul>					
OS:	: Maculopatica atrofica Lieve pallore temporale del pervo ottico					
	Haculopatica attor	ica, cieve panore a		0 00000		
ост	(Optical Cohe	rence Tomogr	aphy)			
		Spessore Fibre	Nervose Peripa	ipapillari (RNFL th)		
	temporale (µm)	superiore (µm)	nasale (µm)	inferiore (µm)	totale (µm)	
OD:	51,33	95,25	67,09	104,80	79,62	
OS:	61,76	100,20	62,32	104,61	81,95	
ост	(Optical Cohe	rence Tomogr	aphy)			
	Volume Maculare (mm <sup>3</sup> )					
	OD: 5,21		<b>OS:</b> 5,4	<b>OS:</b> 5,48		
	Descrizione					
OD:	<ul> <li>Difficoltà operative per deficit di fissazione: spessore medio globale delle fibre nervose parapapillari nella norma con significativo deficit settoriale Temporale . Volumetria maculare ridotta per atrofia centrale</li> </ul>					
OS:	Difficoltà operative per deficit di fissazione: spessore medio globale delle fibre nervose parapapillari nella norma con modesto deficit settoriale Temporale . Volumetria maculare ridotta per atrofia centrale					

### PERG a 60' (stimolazione extramaculare) e a 15'(stimolazione maculare): tracciati: morfologicamente ben strutturati, con tempi di latenza nella norma ed ampiezze ridotte. PEV a

60' (stimolazione extramaculare) e a 15'(stimolazione maculare): tracciati morfologicamente ben strutturati, con aumento dei tempi di latenza ed ampiezze nei limiti della norma. Tempo retino corticale superiore ai limiti della norma a 60' e a 15' di stimolazione.

#### Risposte elettrofunzionali - OS

PERG a 60' (stimolazione extramaculare) e a 15'(stimolazione maculare): tracciati:

60' (stimolazione extramaculare) strutturati, con aumento dei tem corticale superiore ai limiti della	pi a 15'(stimolazione maculare): tracciati morfologicamente ben pi di latenza ed ampiezze nei limiti della norma. Tempo retino norma a 60' e a 15' di stimolazione.
Conclusioni - OD	
Si rilevano alterazioni funzionali o ritardo della conduzione nervosa papillo-maculare	degli strati interni retinici (cellule e fibre ganglionari). Si rileva post-retinica lungo gli assoni di grosso calibro e lungo il fascio
Conclusioni - OS	
Si rilevano alterazioni funzionali o ritardo della conduzione nervosa papillo-maculare	degli strati interni retinici (cellule e fibre ganglionari). Si rileva post-retinica lungo gli assoni di grosso calibro e lungo il fascio

**Discussion/Conclusion:** Mutations in CYP2U1 are associated with both pure and complicated forms of HSP. White matter lesions, basal ganglia calcifications, thin corpus callosum, mental retardation, infraclinical axonal motor and sensory neuropathy have been described. "Maculopathy" has been only found in one female patient in the original paper describing SPG56. This is the first formal report of pigmentary degenerative maculopathy associated with CYP2U1 mutation, which may reasonably be explained by the mitochondrial pathogenesis of the disorder.

## References

1. Tesson C, Nawara M, Salih MAM, et al. Alteration of Fatty-Acid-Metabolizing Enzymes Affects Mitochondrial Form and Function in Hereditary Spastic Paraplegia. American Journal of Human Genetics. 2012;91(6):1051-1064. 2. Citterio A, Arnoldi A, Panzeri E, D'Angelo MG, Filosto M, Dilena R, Arrigoni F, Castelli M, Maghini C, Germiniasi C, Menni F, Martinuzzi A, Bresolin N, Bassi MT. Mutations in CYP2U1, DDHD2 and GBA2 genes are rare causes of complicated forms of hereditary spastic paraparesis. J Neurol. 2014 Feb;261(2):373-81



10-13 OTTOBRE 2015 – GENOVA	

